Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins

• US 7,795,389 B2
• Filed: 09/28/2005
• Issued: 09/14/2010
• Est. Priority Date: 09/28/2004
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Sun, LuZhe, Hinck, Andrew P.
• Primary Examiner(s): Kemmerer; Elizabeth C.
• Assistant Examiner(s): Xie; Xiaozhen
• Application Number:
  US11/238,172
• Publication Number:
  US 20070244042A1
• Time in Patent Office: 1,812 Days
• Field of Search: None
• US Class Current: 530/350
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 14/71 for growth factors; for growth regulators
• CPC Class Codes: C07K 2319/32 fusions with soluble part of a cell surface receptor, "decoy receptors"

Abstract

Anti-cancer agents and/or transforming growth factor beta (TGF-beta or TGFβ) antagonists are disclosed, where the agents and/or antagonists include a therapeutically effective amount of a combination of therapeutically active portions of sRII and therapeutically active portions of sRIII or a fusion polypeptide or protein comprising therapeutically active portions of sRII and therapeutically active portions of sRIII. Methods for preventing, treating and/or ameliorating the symptoms of cancer are also disclosed based on administering an effective amount of a composition of this invention.

Claims

1. A pharmaceutical composition comprising a therapeutically effective amount of a mixture of:

(a) a soluble type II receptor (sRII) which comprises (i) the extracellular domain of the TGFβ

type II receptor or (ii) SEQ ID NO;

2; and

(b) a soluble type III receptor (sRIII) which comprises SEQ ID NO;

4.

2. The composition of claim 1, wherein the composition comprises a soluble type II receptor which comprises SEQ ID NO:

2.

3. The composition of claim 1, wherein the soluble type II receptor is the extracellular domain of the TGFβ

type II receptor.

4. The composition of claim 2, wherein the soluble type II receptor consists of SEQ ID NO:

2.

5. The composition of claim 1, wherein the soluble type III receptor consists of SEQ ID NO:

4.

6. The composition of claim 5, wherein the soluble type II receptor consists of SEQ ID NO:

2.

7. A pharmaceutical composition comprising a therapeutically effective amount of SEQ ID NO:

4.

8. The composition of claim 7, wherein the composition further comprises a therapeutically effective amount of SEQ ID NO:

2.